Cytokinetics, Inc. (CYTK) Posts Q2 EPS Loss of $0.23, Well Below Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $61.23 -1.76%
Revenue Growth %: +2,004.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +2,004.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $6.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cytokinetics to Announce Third Quarter Results on November 4, 2026
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
